BBIO Latest Headlines

Barclays Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

at www.tipranks.com (Mon, 2-Nov 3:58 AM)

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

at www.tipranks.com (Sat, 31-Oct 8:09 PM)

BridgeBio’s Preferred Stock Structure Puts Common Shareholders at Risk of Subordination, Dilution, and Governance Uncertainty

at www.tipranks.com (Sat, 31-Oct 2:00 AM)

Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Fortrea Holdings Inc. (FTRE) and BridgeBio Pharma (BBIO)

at www.tipranks.com (Fri, 30-Oct 2:40 PM)

BridgeBio Pharma (BBIO) Gets a Buy from RBC Capital

at www.tipranks.com (Fri, 30-Oct 9:06 AM)

BridgeBio Pharma (BBIO) Receives a Rating Update from a Top Analyst

at www.tipranks.com (Fri, 30-Oct 9:01 AM)

Cantor Fitzgerald Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

at www.tipranks.com (Fri, 30-Oct 8:54 AM)

Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), BridgeBio Pharma (BBIO)

at www.tipranks.com (Fri, 30-Oct 8:50 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Fri, 30-Oct 8:02 AM)

Analysts Offer Insights on Healthcare Companies: Resmed (RMD), BridgeBio Pharma (BBIO) and Kymera Therapeutics (KYMR)

at www.tipranks.com (Fri, 30-Oct 6:40 AM)

BridgeBio Therapeutics: Solid Attruby Momentum and Pipeline Upside Balanced by Execution Risks; Eric Joseph Reiterates Hold Rating and Maintains $91 Price Target

at www.tipranks.com (Fri, 30-Oct 6:35 AM)

BridgeBio’s oral infigratinib wins FDA Priority Review, setting a February 4, 2027 PDUFA date for achondroplasia NDA

Market Chameleon (Tue, 6-Oct 8:18 AM)